Last reviewed · How we verify
Gantrisin (SULFISOXAZOLE ACETYL)
At a glance
| Generic name | SULFISOXAZOLE ACETYL |
|---|---|
| Sponsor | Roche |
| Target | Endothelin B receptor, Endothelin-1 receptor, Dihydropteroate synthase |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
| First approval | 1953 |
Approved indications
Common side effects
- Nausea
- Vomiting
- Abdominal pain
- Diarrhea
- Anorexia
- Rash
- Urticaria
- Pruritus
- Headache
- Dizziness
- Flatulence
- Weakness
Serious adverse events
- Anaphylaxis
- Stevens-Johnson syndrome
- Toxic epidermal necrolysis
- Pseudomembranous colitis
- Ventricular tachycardia
- Torsade de pointes
- Acute renal failure
- Aplastic anemia
- Agranulocytosis
- Hepatic necrosis
Key clinical trials
- Patients Response to Early Switch To Oral:Osteomyelitis Study (EARLY_PHASE1)
- Trimethoprim/Sulfamethoxazole Combined With Caspofungin as First-line Therapy in PCP (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gantrisin CI brief — competitive landscape report
- Gantrisin updates RSS · CI watch RSS
- Roche portfolio CI